Sanofi to Buy Caprelsa Drug from AstraZeneca for $300 Million
This article is for subscribers only.
Sanofi agreed to buy a medicine called Caprelsa for as much as $300 million from AstraZeneca Plc to boost its rare disease medicine offerings.
The French drugmaker’s Genzyme unit will pay AstraZeneca $165 million upfront to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135 million, it said in a statement.